Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546133 | 0.89 | SYK (0.47) | CYP2C19BRAFCYP3A4CYP2C9SYK | |
| SCHEMBL12258883 | 0.88 | KDR (0.41) | CYP2C19SYKKDR | |
| SCHEMBL2535903 | 0.88 | CYP3A4 (0.42) | CYP2C19BRAFCYP3A4CYP2C9SYK | |
| SCHEMBL2546043 | 0.85 | CYP3A4 (0.49) | CYP2C19BRAFCYP3A4CYP2C9KIT | |
| SCHEMBL2539858 | 0.84 | CYP2C19 (0.40) | CYP2C19BRAFCYP3A4CYP2C9SYK | |
| SCHEMBL2544440 | 0.81 | CYP3A4 (0.35) | CYP3A4CYP2C9SYKFLT3 | |
| SCHEMBL2536418 | 0.80 | CYP2C19 (0.68) | CYP2C19CYP3A4CYP2C9KITKDR | |
| SCHEMBL2538828 | 0.80 | SYK (0.46) | CYP2C19BRAFCYP3A4CYP2C9SYK | |
| SCHEMBL2561618 | 0.79 | CYP3A4 (0.39) | CYP2C19CYP3A4 | |
| SCHEMBL2559886 | 0.79 | CYP3A4 (0.42) | CYP2C19CYP3A4CYP2C9SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2560972-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2560972-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9682981-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682981-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2015-07-02 | — | — | US | disclosed |
| US-8901118-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2560972-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133637-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133637-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, NTRK1, PRKDC | CYP2C19 3444/4885BRAF 33/4885CYP3A4 3791/4885 |
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | CYP2C19 3417/4885BRAF 29/4885CYP3A4 3835/4885 |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | CYP2C19 3527/4885BRAF 39/4885CYP3A4 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.